Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron ® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron ® , currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim... Read More

Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) Top-line results from the Bateman Horne Center’s Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. ( Nasdaq: VIRI) (the... Read More

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets.... Read More

Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company... Read More

ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a... Read More

ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the pricing of its previously announced public offering of 8,500,000 shares of its common stock at a... Read More

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that it intends to offer and sell up to $2.1 million in shares of its common stock in a public offering.... Read More

Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 Conference Call Today at 8:30 a.m. ET ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating... Read More

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets.... Read More

New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios... Read More

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the fourth quarter and full year ended December 31, 2023. Key Highlights and Upcoming Milestones Virios... Read More

ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today issued a Shareholder Letter highlighting the Company’s progress and key milestones in 2024. Dear Virios (VIRI) Shareholders, On behalf... Read More

Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced... Read More

ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced receipt of the Food and Drug Administration’s (“FDA”) feedback on requirements for advancing IMC-2 (combination of valacyclovir... Read More

Conference Call Today at 8:30 a.m. ET ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and... Read More

ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial... Read More

ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID , announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00... Read More

ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional... Read More

ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors... Read More

ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that it has advised its sales agent, JonesTrading Institutional Services LLC (“JonesTrading”), to cease sales under the Capital on Demand... Read More

Continued Progress in Expanding and Advancing Clinical Pipeline Conference Call Today at 8:30 a.m. ET ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, today announced financial results for the second... Read More

ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that the Food & Drug Administration (“FDA”) communicated that, following their initial review of the Company’s chronic toxicology program,... Read More

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report second quarter 2023 financial results on Thursday, August 10, 2023 before the open of the financial... Read More

ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that female patients diagnosed with Long-COVID illness, otherwise known as Post-Acute Sequelae of COVID-19 infection (“PASC”), exhibited clinically and... Read More

ATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Below are some recent key developments in the business, including the Company regaining compliance with the minimum bid price requirement. Key... Read More

ATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it has submitted final toxicology reports as per Food & Drug Administration (“FDA”) request as part of their overall review of the Company’s Phase... Read More

ATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the first quarter ended March 31, 2023. Key Highlights The Company proposed a Phase 3 program for its lead development candidate... Read More

ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets. About... Read More

Virios’ IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results Final Toxicology Results to be Submitted to FDA in May 2023 Company will Provide Material Updates on Further FDA Guidance as Process Proceeds for This Important FDA “Fast-track” Designated Program ATLANTA, April 24, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc.... Read More

ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced financial results for the fourth quarter and full year ended December 31, 2022. Key Highlights Based on extensive analysis of the data generated from... Read More

ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), announced today that it will report fourth quarter and full year 2022 financial results on Tuesday, March 14, 2023 before the open of the financial markets. Given the upcoming... Read More

ATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that it expects top-line results from its Phase 2 Post-Acute Sequelae of COVID-19 (also known as PASC or Long-COVID) exploratory clinical trial to be... Read More

ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia (“FM”), announced today that its end-of-Phase 2 meeting request with the U.S. Food and Drug Administration (“FDA”) to discuss advancing IMC-1 into Phase 3 development as a... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The Company intends to use the net... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study of oral IMC-1 for the treatment of FM. Overall,... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”), today announced commencement of enrollment in its exploratory Long-COVID trial. This study is supported via an unrestricted investigational grant to the Bateman Horne Center, a non-profit, interdisciplinary... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022. Key Highlights and Upcoming Milestones Completed patient dosing in Phase 2b FORTRESS fibromyalgia study Top line FORTRESS results expected in... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Q3 Virtual Investor Summit. During the presentation, the Company will provide an overview of its... Read More

PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios Therapeutics, Inc. (NASDAQ: VIRI) is anticipating the reporting of phase 2b treatment results for its lead fibromyalgia treatment candidate this September and continues to add value... Read More

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that its second quarter 2022 financial results will be reported on Thursday, August 11, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August... Read More